Journal article
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
- Abstract:
-
Background
Aiming to improve treatment options for BRAF wild-type melanoma, we previously conducted the DOC-MEK study of docetaxel with MEK inhibitor (MEKi) selumetinib or placebo, revealing trends to prolongation of progression-free survival (hazard ratio 0.75, P = 0.130), and improved response rates (32% vs 14%, P = 0.059) with docetaxel plus selumetinib. NRAS status did not associate with outcome. Here, the aim was to identify novel biomarkers of response to MEKi...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, 1.4MB)
-
- Publisher copy:
- 10.1038/s41416-019-0673-5
Why is the content I wish to access not available via ORA?
Bibliographic data (the information relating to research outputs) and full-text items (e.g. articles, theses, reports, etc.) arrive in ORA from several different sources. Unfortunately we are not able to make available the full-text for every research output.
Please contact the ORA team (
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
Content may be unavailable for the following four reasons
-
Version unsuitable
-
We have not obtained a suitable full-text for a given research output. See this page for more information.
-
Recently completed
-
Sometimes content is held in ORA but is unavailable for a fixed period of time to comply with the policies and wishes of rights holders.
-
Permissions
-
All content made available in ORA should comply with relevant rights, such as copyright. See this page for more information.
-
Clearance
-
Some thesis volumes scanned as part of the digitisation scheme funded by Dr Leonard Polonsky are currently unavailable due to sensitive material or uncleared third-party copyright content. We are attempting to contact authors whose theses are affected.
Alternative access to the full-text
You may be able to access the full-text directly from the publisher's website using the 'Publisher Copy' link in the 'Links & Downloads' box from a research output's ORA record page. This method may require an institutional or individual subscription to the journal/resource.
Authors
Funding
Cancer Research UK
More from this funder
Bibliographic Details
- Publisher:
- Springer Nature Publisher's website
- Journal:
- British Journal of Cancer Journal website
- Volume:
- 122
- Issue:
- 4
- Pages:
- 506-516
- Publication date:
- 2020-02-18
- Acceptance date:
- 2019-11-15
- DOI:
- EISSN:
-
1532-1827
- ISSN:
-
0007-0920
- Pmid:
-
31839677
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
1078864
- Local pid:
- pubs:1078864
- Deposit date:
- 2020-08-15
Terms of use
- Copyright holder:
- Gupta, A et al.
- Copyright date:
- 2020
- Rights statement:
- © The Author(s), under exclusive licence to Cancer Research UK 2019.
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from Springer Nature at: https://doi.org/10.1038/s41416-019-0673-5
If you are the owner of this record, you can report an update to it here: Report update to this record